An Open-label, Multi-center, Dose-escalation and Expansion Study to Evaluate the Safety and Efficacy of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs ONO 7579 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms ONTRK
- Sponsors Ono Pharmaceutical
- 09 Feb 2018 Status changed from active, no longer recruiting to discontinued.
- 16 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2017 Status changed from not yet recruiting to recruiting.